Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas by Gong, Yixuan et al.
Induction of BIM Is Essential for Apoptosis
Triggered by EGFR Kinase Inhibitors in Mutant
EGFR-Dependent Lung Adenocarcinomas
Yixuan Gong
1, Romel Somwar
2, Katerina Politi
2, Marissa Balak
1, Juliann Chmielecki
1, Xuejun Jiang
3, William Pao
1*
1 Pao Laboratory, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America, 2 Varmus
Laboratory, Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America, 3 Cell Biology Program, Memorial
Sloan-Kettering Cancer Center, New York, New York, United States of America
Funding: This work was supported
by the American Cancer Society-
Davidson Sinai Research Foundation
Post-doctoral Fellowship PF-05-078-
01-MGO (KP); The Carmel Hill Fund
(RS and KP); NIH R01CA113890 (XJ);
the Doris Duke Charitable
Foundation for non-animal work
(WP); Joan’s Legacy: The Joan
Scarangello Foundation to Conquer
Lung Cancer (WP); K08-CA097980
(WP); the Thomas G. Labrecque
Foundation (WP), and funds from
the Miner Family (WP). These funders
had no role in the study design, data
collection and analysis, decision to
publish, or preparation of the
manuscript.
Competing Interests: The authors
have declared that no competing
interests exist.
Academic Editor: Ingo K.
Mellinghoff, University of California
Los Angeles, United States of
America
Citation: Gong Y, Somwar R, Politi K,
Balak M, Chmielecki J, et al. (2007)
Induction of BIM is essential for
apoptosis triggered by EGFR kinase
inhibitors in mutant EGFR-
dependent lung adenocarcinomas.
PLoS Med 4(10): e294. doi:10.1371/
journal.pmed.0040294
Received: April 5, 2007
Accepted: August 28, 2007
Published: October 9, 2007
Copyright:  2007 Gong et al. This
is an open-access article distributed
under the terms of the Creative
Commons Attribution License, which
permits unrestricted use,
distribution, and reproduction in any
medium, provided the original
author and source are credited.
Abbreviations: IC50, concentration
of drug required for 50% growth
inhibition; PI, propidium iodide;
siRNA, small interfering RNA; TKI,
tyrosine kinase inhibitor
* To whom correspondence should
be addressed. E-mail: paow@mskcc.
org
ABSTRACT
Background
Mutations in the epidermal growth factor receptor (EGFR) gene are associated with increased
sensitivity of lung cancers to kinase inhibitors like erlotinib. Mechanisms of cell death that occur
after kinase inhibition in these oncogene-dependent tumors have not been well delineated. We
sought to improve understanding of this process in order to provide insight into mechanisms
of sensitivity and/or resistance to tyrosine kinase inhibitors and to uncover new targets for
therapy.
Methods and Findings
Using a panel of human lung cancer cell lines that harbor EGFR mutations and a variety of
biochemical, molecular, and cellular techniques, we show that EGFR kinase inhibition in drug-
sensitive cells provokes apoptosis via the intrinsic pathway of caspase activation. The process
requires induction of the proapoptotic BH3-only BCL2 family member BIM (i.e., BCL2-like 11, or
BCL2L11); erlotinib dramatically induces BIM levels in sensitive but not in resistant cell lines, and
knockdown of BIM expression by RNA interference virtually eliminates drug-induced cell killing
in vitro. BIM status is regulated at both transcriptional and posttranscriptional levels and is
influenced by the extracellular signal-regulated kinase (ERK) signaling cascade downstream of
EGFR. Consistent with these findings, lung tumors and xenografts from mice bearing mutant
EGFR-dependent lung adenocarcinomas display increased concentrations of Bim after erlotinib
treatment. Moreover, an inhibitor of antiapoptotic proteins, ABT-737, enhances erlotinib-
induced cell death in vitro.
Conclusions
In drug-sensitive EGFR mutant lung cancer cells, induction of BIM is essential for apoptosis
triggered by EGFR kinase inhibitors. This finding implies that the intrinsic pathway of caspase
activation may influence sensitivity and/or resistance of EGFR mutant lung tumor cells to EGFR
kinase inhibition. Manipulation of the intrinsic pathway could be a therapeutic strategy to
enhance further the clinical outcomes of patients with EGFR mutant lung tumors.
The Editors’ Summary of this article follows the references.
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Lung adenocarcinomas that harbor somatic kinase domain
mutations in the epidermal growth factor receptor (EGFR)
are highly likely to respond to the EGFR tyrosine kinase
inhibitors geﬁtinib (Iressa) and erlotinib (Tarceva) [1–3]. One
possible explanation for this phenomenon is that the cancer
cells are ‘‘addicted’’ to signaling via the mutant EGFRs and
die when the mutant oncoprotein is inactivated. However,
speciﬁc mechanisms underlying erlotinib-induced cell death
have not been well delineated.
To date, drug responses have been characterized in limited
detail in a few drug-sensitive human lung adenocarcinoma
cell lines that harbor EGFR mutations. These studies indicate
that EGFR kinase inhibitors can induce the activation of
cysteine aspartyl-speciﬁc proteases (caspases) in EGFR mu-
tant cells [4–7]. Similarly, analyses of mouse models of drug-
sensitive mutant EGFR-driven lung adenocarcinomas have
demonstrated that erlotinib induces caspase activation [8,9].
However, none of these studies addressed the molecular
mechanisms by which caspases are activated.
Two major pathways of caspase activation exist: the
extrinsic pathway, triggered by ‘‘death receptor’’-ligand
binding (such as FASL to FAS), and the intrinsic pathway,
triggered by cellular stress, such as occurs after cytokine
deprivation, DNA damage, and anoikis (reviewed in [10]).
BCL2 family proteins are a critical feature of the intrinsic
pathway. Overexpression of some antiapoptotic family
members, such as BCL2 and BCL-xL (also called BCL2-like
ligand 1 [BCL2L1]), can prevent apoptosis induced by
withdrawal of growth factor [11,12]. Control of stability of
the BCL2-related antiapoptotic myeloid cell leukemia se-
quence 1 (MCL1) protein is also an important mechanism for
the regulation of apoptosis by growth factors [13]. BCL2-
associated X protein (BAX) and BCL2 antagonist/killer (BAK),
on the other hand, are proapoptotic BCL2 family members.
Deletion of both renders cells highly resistant to apoptosis
following growth factor withdrawal [14,15]. During apoptosis,
BAX translocates to mitochondria, causing release of
cytochrome c into the cytosol [16].
A third proapoptotic subgroup of the BCL2 family includes
BIM (also known as BCL2L11 [BCL2-like 11]), BAD (BCL2-
antagonist of cell death), and BBC3 (BCL2-binding compo-
nent 3; also called PUMA), which all contain a ‘‘BH3’’ protein
domain. These BH3-only members of the BCL2 family
promote apoptosis when overexpressed [17,18] by inhibiting
antiapoptotic members and/or directly activating BAX/BAK
[19,20]. Bim is induced in interleukin 3 (IL3)-dependent
murine hematopoietic cells by IL-3 deprivation but not by
other apoptotic triggers, such as DNA damage or Fas [21].
BIM is one of the most potent proapoptotic BH3-only
proteins; unlike BAD, BIM binds to all prosurvival BCL2
family members with high afﬁnity [19]. Recent analyses of
IL3-dependent cell lines from mice lacking the genes for Bad,
Bim, Puma, Bad and Bim, or Bax and Bak, showed that while
Bad and Bim were not required for cell death following IL3
withdrawal, cell death did in part depend upon Puma [22].
Mechanisms of death in leukemic cells that depend upon
signaling from the Bcr-Abl oncoprotein for survival may be
different from those in cells that depend upon IL3, as studies
using RNA interference and cells from gene-targeted mice
revealed that the combined loss of Bim and Bad abrogates cell
killing induced by the kinase inhibitor imatinib (Gleevec) [23].
In this study, we sought to determine the mode of cell death
induced by EGFR kinase inhibitors in drug-sensitive human
lung adenocarcinoma cells that harbor EGFR mutations. We
hoped that an improved understanding of this process could
provide insight into mechanisms of sensitivity and/or resist-
ance to tyrosine kinase inhibitors (TKIs) and uncover new
targets for therapy.
Methods
Cell Culture
The human lung adenocarcinoma cell lines H3255, PC-9,
H1650, and H1975 were described previously [4–7,24]. Cells
were maintained in a humidiﬁed incubator with 5% CO2 at
37 8C in RPMI 1640 medium (ATCC, Manassas, VA)
supplemented with 10% fetal bovine serum and pen-strep
solution (both from Gemini Bio-Products, West Sacramento,
CA; ﬁnal concentrations of 100 U/ml penicillin G and 100 lg/
ml streptomycin, respectively). NIH 3T3 cells stably trans-
fected with various EGFR cDNAs were kindly provided by M.
Meyerson [25]. BCL-xL-overexpressing PC-9 cells were
generated by transfecting parental cells with pcDNA3.1( )
hygromycin vector carrying a BCL-xL cDNA [26] using Fugene
6 transfection reagent (Roche Diagnostics, Indianapolis, IN).
Resistant clones were selected in 250 lg/ml hygromycin B
(Invitrogen, Carlsbad, CA) for 12 d, isolated using cloning
cylinders, and subsequently expanded in hygromycin B-
containing medium. Control cells were transfected with
empty pcDNA3.1( ) hygromycin vector.
Reagents
Erlotinib was synthesized by the Organic Synthesis Core
Facility at Memorial Sloan-Kettering Cancer Center. Geﬁti-
nib was kindly provided by AstraZeneca (Wilmington, DE).
ABT-737 and its inactive enantiomer were kindly provided by
Abbott Laboratories (Abbott Park, IL). The Vybrant Apopto-
sis Assay Kit #2 was from Invitrogen. CellTiter Blue Reagent
and APO-ONE Homogenous Caspase3/7 assay kits were from
Promega (Madison, WI). Propidium iodide and actinomycin D
were from Sigma-Aldrich (St. Louis, MO). CL-387,785, U0126,
PD98059, LY294002, and wortmannin were from Calbiochem
(San Diego, CA).
Antibodies
Cytochrome c-, MCL1-, and EGFR-speciﬁc antibodies were
from BD Biosciences (San Jose, CA). Anti-actin antibody was
from Sigma-Aldrich. Anti-BCL-2, -BCL-xL, -BAX, -BAD,
-BIM, -PUMA, -pERK (Thr202/Tyr204), -ERK, -pAKT
(Ser473), -AKT, and -pEGFR (Tyr1092) antibodies, and
secondary antibodies including HRP-conjugated anti-mouse
and anti-rabbit antibodies, were purchased from Cell Signal-
ing Technology (Danvers, MA). (Note that EGFR has two
numbering systems. The ﬁrst denotes the initiating methio-
nine in the signal sequence as amino acid  24. The second
denotes the methionine as amino acid þ1. Commercial
antibodies, such as the Y1068-speciﬁc anti-phospho-EGFR,
use the ﬁrst nomenclature. In the second nomenclature,
which we use here, Y1068 is Y1092.) BAK-speciﬁc antibody
was from Lab Vision Corporation (Fremont, CA). L858R
EGFR antisera was previously described [9]. Anti-total EGFR
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were from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell Viability Assay
Cells were seeded in 96-well plates at a density of 5,000 cells
in triplicates and treated with different concentrations of
erlotinib on the following day. The viability of erlotinib-
treated cells was measured at 24, 48, and 72 h post-treatment
using CellTiter Blue Reagent (Promega). Caspase 3/7 activity
was monitored in the same wells using the APO-ONE
Homogenous Caspase 3/7 assay kit (Promega).
Flow Cytometry Analysis
Cells were collected, washed with PBS, and ﬁxed in 70%
ethanol for at least 1 h. Prior to FACS analysis, cells were
washed twice with cold PBS and resuspended in PBS
containing 200 lg/ml RNase, 50 lg/ml propidium iodide
(PI), and 0.1% sodium citrate. Flow cytometry was performed
on a Becton-Dickinson FACSCalibur ﬂow cytometer. Data
were processed using FlowJo ﬂow cytometry analysis software
(http://www.ﬂowjo.com/). Annexin V/PI apoptosis assays (In-
vitrogen) were performed according to manufacturer’s
instructions.
Subcellular Fractionation
Subcellular fractionation was performed as described
previously [26].
Immunoblotting
Cells were scraped from 10 cm petri dishes, washed twice
with PBS, and then incubated in lysis buffer [27] containing
protease inhibitor cocktail (Roche Diagnostics), 40 mM
sodium ﬂuoride, and 1 mM sodium orthovanadate for 30
min. The supernatants were subjected to SDS-PAGE (gels
from Invitrogen) followed by blotting with indicated anti-
bodies and detected by Supersignal West Pico Luminol/
Enhancer Solution (Pierce Biotechnology, Rockford, IL).
Immunofluorescence and Confocal Imaging
Cells were grown in Lab-Tek II chambers (Nalge Nunc
International, Naperville, IL), ﬁxed in 4% (vol/vol) parafor-
maldehyde solution for 10 min at room temperature,
permeabilized in 0.5% Triton X-100 solution for 10 min,
incubated in blocking solution (5% BSA) for 1 h at room
temperature and incubated with primary antibody (1:100) in
5% BSA overnight at 4 8C. After 1 h incubation with FITC- or
rhodamine-conjugated secondary antibody (1:500), slides
were mounted in Vectashield mounting medium (Vector
Laboratories, Burlingame, CA). Digital images were obtained
with a Leica inverted confocal microscope.
Gene Silencing by siRNA
Cells were seeded into six-well plates at a density of 1.25 3
10
5 cells/well. After 24 h, cells were transfected with various
small interfering RNAs (siRNAs) against GFP, BIM,o rBAD,
using DharmaFECT 1 transfection reagent as per manufac-
turer’s instructions. GFP siRNA and BIM siRNA-2 were
obtained from the High Throughput Core Facility (Memorial
Sloan-Kettering Cancer Center, New York, NY). BAD siRNA
and BIM siRNA-1 were from Dharmacon (siGENOME
SMARTpool, Dharmacon, Chicago, IL). Cells were harvested
48 h after transfection, and lysates were analyzed for BIM
expression by immunoblotting analysis.
Animal Husbandry and Genotyping
The generation, maintenance, genotyping, and drug treat-
ment of bitransgenic lung tumor-bearing mice that express a
tetracycline-inducible exon 19 deletion mutant (EGFR
DL747–
S752) or the L858R mutant (EGFR
L858R)i nm o u s el u n g
epithelia have been previously described [9]. Animals were
humanely killed with a lethal dose of CO2 per institutional
guidelines. The lungs were excised, ﬂash-frozen in liquid
nitrogen, and crushed for protein extraction in lysis buffer
supplemented with protease and phosphatase inhibitors.
For xenograft studies, the hind ﬂanks of 4- to 6-wk-old
female athymic (nu/nu) nude mice (NCI-Frederick Cancer
Center, Frederick, MD) were injected subcutaneously with 10
3 10
6 PC-9 cells resuspended in 100 ll of Matrigel (BD
Biosciences). Tumor-bearing animals (12 d after injection)
were administered either vehicle control or 25 mg/kg
erlotinib intraperitoneally every 12 h 3 2 doses and then
humanely killed 24 h after the ﬁrst injection. Xenografts were
excised, ﬂash-frozen in liquid nitrogen, and crushed for
protein extraction in lysis buffer supplemented with protease
and phosphatase inhibitors.
All animals were kept in speciﬁc pathogen-free housing
with abundant food and water under guidelines approved by
the Memorial Sloan-Kettering Cancer Center Institutional
Animal Care and Use Committee and Research Animal
Resource Center.
Results
EGFR Kinase Inhibition Induces G1 Cell Cycle Arrest in
Drug-Sensitive Lung Adenocarcinoma Cells with EGFR
Mutations
A number of lung adenocarcinoma cell lines have been
reported to harbor drug-sensitizing EGFR mutations [4–7,24].
To verify these ﬁndings, we obtained four of these cell lines
and determined their mutation status by direct Sanger-based
resequencing of EGFR exons 18–24 (Table 1). As reported,
PC-9 and H1650 cells contained the in-frame exon 19
deletion that eliminates amino acids ELREA (del E746–
A750). H3255 and H1975 harbored the exon 21 T!G point
mutation at nucleotide position 2,573, which substitutes
arginine for leucine at position 858 (L858R). H1975 cells also
contained the exon 20 C!T mutation at nucleotide position
2,369. This change leads to substitution of methionine for
threonine at position 790 (T790M) and is associated with
acquired resistance to geﬁtinib and erlotinib [24].
Table 1. Sensitivity of EGFR-Mutant Lung Adenocarcinoma Cell
Lines to Erlotinib
Cells Mutation IC50 (lM)
H3255 L858R 0.01
PC-9 Del E746–A750 0.04
H1650 Del E746–A750 .1
H1975 L858R, T790M .10
Cells were examined for mutations in EGFR by dideoxynucleotide sequencing of PCR
products spanning individual exons (18–24). The IC50 values were determined using
CellTiter Blue assays as described in Methods. Del, deletion; amino acids noted using
single-letter abbreviations.
doi:10.1371/journal.pmed.0040294.t001
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using a cell viability assay that measures a colorimetric signal
produced by conversion of resazurin to resoruﬁn, which is
directly proportional to the numbers of viable cells. Cells
were grown in 10% serum for 72 h in different concen-
trations of erlotinib. As previously reported, the concen-
tration of drug required for 50% growth inhibition (IC50)o f
two lines—H3255 and PC-9—was in the nanomolar range (10
nM and 40 nM respectively) (Table 1). The IC50 values
corresponded with the degrees of inhibition of phosphor-
ylation of EGFR and key components of downstream signal-
ing cascades (i.e., ERK and AKT), as seen by immunoblotting
lysates derived from the lines treated with various concen-
trations of drug with phospho-speciﬁc antibodies (Figure 1).
H1650 cells had an intermediate sensitivity (Table 1).
Consistent with this ﬁnding, H1650 lysates displayed incom-
plete inhibition of ERK and AKT pathways (Figure 1), the
latter possibly due to lack of expression of the phosphatase
and tensin homolog (PTEN) protein, which negatively
regulates the phosphatidylinositol 3-kinase signaling cascade
downstream of EGFR [28]. H1975 cells were insensitive to
erlotinib due to the drug-resistant T790M mutation [24].
Sensitivity of cells to erlotinib could result from an arrest
of cells in a speciﬁc stage of the cell cycle. To investigate this
possibility, we treated the four cell lines with either DMSO or
erlotinib and then analyzed their DNA content by FACS after
staining with the DNA-intercalating dye PI. After 24 h of 100
nM erlotinib treatment, both drug-sensitive cell lines (H3255
and PC-9) showed an increase in the proportion of cells in the
G1 phase and a decrease in the proportion of cells in S phase,
compared to untreated cells (Figure 2A). These results
indicate that erlotinib induces G1 cell cycle arrest in drug-
sensitive lung adenocarcinoma cells with EGFR mutations.
H1650 cells, treated with a higher dose (500 nM) of erlotinib,
displayed only a slight increase in the proportion of cells in
the G1 phase compared to control-treated cells. Minimal
changes were observed after treatment of drug-resistant
H1975 cells.
EGFR Kinase Inhibition Induces Apoptosis in H3255 and
PC-9 Cells
We next investigated whether erlotinib also induced
apoptosis in the cell lines with nanomolar sensitivity. Cells
treated with DMSO or different concentrations of erlotinib
for 48 h were stained with FITC-conjugated annexin V and PI,
and percentages of apoptotic cells were measured by FACS.
(The phospholipid-binding protein annexin V has a high
afﬁnity for phosphatidylserine, which is translocated from the
inner to the outer leaﬂet of the plasma membrane during the
early phases of apoptosis, and PI penetrates the plasma
membrane of cells only when membrane integrity is
breached, as occurs in the later stages of apoptosis.) After
exposure to escalating concentrations of drug, PC-9 and
H3255 cells demonstrated dose-dependent increases in the
percentages of annexin V- and PI-positive cells (Figure 2B).
Consistent with these ﬁndings, the activity of downstream
‘‘executioner’’ caspases, caspases 3 and 7, in lysates from cells
treated with erlotinib at various concentrations for various
times, was also increased in both dose- and time-dependent
fashion (Figure S1). By contrast, minimal increases in the
percentage of annexin V- and PI-positive cells were observed
in drug-treated H1650 and H1975 cells, even at higher doses
of erlotinib (1 lM) (Figure 2B).
Mutant EGFR-Dependent Cells Die via the Intrinsic
Pathway of Apoptosis
We subsequently examined mechanisms of apoptosis in the
two cell lines that undergo apoptosis in response to erlotinib.
Caspases can be activated via two major pathways: the
extrinsic pathway, triggered by the binding of ligands to
‘‘death receptors,’’ and the intrinsic pathway, triggered by
cellular stress, such as occurs after cytokine deprivation, DNA
damage, and anoikis [10]. Since inhibition of EGFR kinase
activity by erlotinib is similar to growth factor withdrawal, we
investigated whether erlotinib induced the intrinsic pathway
of caspase activation in PC-9 and H3255 cells by a stress-
related mechanism.
One hallmark of the intrinsic pathway of apoptosis is
cytochrome c release from mitochondria [29]. We found by
immunoblotting cytosolic fractions from H3255 cells treated
with erlotinib that cytochrome c levels increased within the
cytosol in both a time- and concentration-dependent manner
(Figure 3A). Similar results were obtained with cytosolic
fractions from drug-treated PC-9 cells (unpublished data).
Changes in the localization of proapoptotic BAX are
another hallmark of the intrinsic pathway of apoptosis [29].
Immunostaining followed by confocal microscopy revealed
that at baseline, BAX was found in the nuclei of both PC-9
and H3255 cells (Figure 3B and unpublished data); the
Figure 1. Effects of Erlotinib on EGFR Signaling Pathways in H3255, PC-9,
H1650, and H1975 Cells
Cells were treated with the indicated concentrations of erlotinib for 6 h.
Cell lysates were analyzed by immunoblotting, using the indicated
antibodies. t, total protein; p, phospho-protein.
doi:10.1371/journal.pmed.0040294.g001
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BIM and Erlotinib-Induced ApoptosisFigure 2. Erlotinib Induces G1 Cell Cycle Arrest and Apoptosis in Drug-Sensitive Lung Adenocarcinoma Cell Lines That Harbor EGFR Mutations
(A) Cell lines treated with either DMSO or indicated concentrations of erlotinib for 24 h were used for cell cycle analysis as described in the Methods.
Data represent the mean 6 standard deviation of three independent experiments.
(B) Cell lines treated with either DMSO or different concentrations of erlotinib for 48 h were used for annexin V/PI apoptosis assays as described in
Methods.
doi:10.1371/journal.pmed.0040294.g002
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BIM and Erlotinib-Induced Apoptosisnuclear localization of BAX in human lung cancer cell lines
has been previously reported [30,31]. Following erlotinib
treatment, BAX was found in the cytoplasm in apoptotic cells.
The distribution of cytochrome c changed from punctate to
more diffuse, consistent with the release of cytochrome c
from mitochondria. Merging of the two ﬂuorescent signals
revealed some overlap between BAX and cytochrome c
staining. These observations suggest that BAX translocates
to mitochondria during erlotinib-induced apoptosis in
mutant EGFR-dependent lung cancer cells.
To verify further whether erlotinib-induced apoptosis is
mediated through the intrinsic apoptotic pathway, we
examined effects of erlotinib on PC-9 cells that stably
overexpress the antiapoptotic BCL-2 family member BCL-
xL. Two stable clones (B1 and B2) were derived, and both
displayed signiﬁcantly higher levels of BCL-xL than did cells
transfected with vector alone (Figure 3C). Compared to
vector-transfected cells, in which 100 nM erlotinib increased
the fraction of annexin V-positive cells by 20% over DMSO-
treated cells, drug treatment in cells overexpressing BCL-xL
increased the fraction of apoptotic cells by only 3%–5% over
DMSO-treated controls (Figure 3D). As expected, BCL-xL did
not affect the inhibition of EGFR signaling by erlotinib. The
drug still inhibited the autophosphorylation of EGFR as well
as the phosphorylation of ERK and AKT (Figure 3E). These
results collectively indicate that erlotinib-induced apoptosis
in mutant EGFR-dependent lung adenocarcinoma cells is
mediated predominantly by the intrinsic apoptotic pathway.
The Status of BIM Is Dramatically Altered by Inhibition of
EGFR Kinase Activity in Cells Dependent upon Mutant
EGFR Signaling for Survival
The intrinsic pathway of apoptosis is regulated by BCL2
family member proteins, some of which are antiapoptotic
(e.g., BCL2, BCL-xL, MCL1) and some proapoptotic (e.g., the
BAX family members BAX and BAK, and the BH3-only
proteins BIM, BAD, and PUMA) [17,18]. To determine which
BCL2 family members are potentially involved in the
maintenance of tumors by mutant EGFR, we studied the
effect of erlotinib treatment on the expression of BCL2, BCL-
xL, MCL1, BAX, BAK, BIM, BAD, and PUMA in H3255 cells.
We found that the expression levels of only the antiapoptotic
protein MCL1 and the proapoptotic BH3-only protein BIM
were signiﬁcantly altered by the drug (Figure 4A).
MCL1 protein is rapidly degraded by the proteasome and
its elimination is required for the initiation of apoptosis
following ultraviolet radiation in HeLa cells [32]. To inves-
tigate if down-regulation of MCL1 is essential for erlotinib-
induced apoptosis in lung adenocarcinoma cells, we blocked
MCL1 degradation with the proteasome inhibitor MG132 in
H3255 cells. Despite the efﬁcient inhibition of MCL1
degradation by MG132, erlotinib was still able to induce
apoptosis as measured by an increase in PARP (poly ADP
ribose polymerase) cleavage (Figure S2). Moreover, MCL1
levels remained constant in erlotinib-treated PC-9 cells,
which also undergo apoptosis in response to drug treatment
(Figure 4B). These results collectively indicate that MCL1
elimination is not essential for erlotinib-induced apoptosis in
mutant EGFR-dependent cells.
We next focused our attention on BIM. Immunoblotting
analysis of the four cell lines revealed that the levels of all
three major splicing isoforms—BIM-extra long (EL), BIM-
long (L), and BIM-short (S)—were induced after erlotinib
treatment in drug-sensitive H3255 and PC-9 cells but not in
drug-resistant H1650 and H1975 cells (Figure 4A and 4B).
Moreover, in the drug-sensitive but not in the drug-resistant
lines, erlotinib appeared to induce signiﬁcant dephosphor-
ylation of BIM EL, as this isoform migrated faster in
polyacrylamide gel electrophoresis after drug treatment
(Figure 4A and 4B). This ﬁnding is notable because others
have shown that dephosphorylation of BIM results in an
increase in its proapoptotic function [33,34].
BIM has been shown to be regulated transcriptionally [35].
To investigate whether the induction of BIM protein by
erlotinib occurred at the transcriptional level in H3255 cells,
we measured BIM proteins in lysates from cells treated for
varying amounts of time with either erlotinib alone or with
erlotinib and the RNA polymerase II inhibitor, actinomycin
D, which inhibits mRNA transcription (Figure 4C). BIM EL
levels rose within 2 h after treatment with the kinase inhibitor
alone and continued to increase up to at least 14 h.
Cotreatment with actinomycin D efﬁciently blocked most of
this increase. Consistent with this, transcriptional proﬁling of
H3255 cells treated with erlotinib showed that levels of BIM
mRNA increased signiﬁcantly 2.5-fold by 12 h after treatment
(unpublished data). These data suggest that augmented
transcription of BIM can account for at least part of the
increase in BIM protein after treatment of mutant EGFR-
dependent cells with erlotinib.
Finally, to determine if induction of BIM was unique to
erlotinib, we examined the status of BIM in H3255 and PC-9
cells treated with erlotinib (100 nM) or two other EGFR
inhibitors: the related reversible EGFR inhibitor geﬁtinib (1
lM) and the irreversible EGFR inhibitor CL-387,785 (100 nM)
[36]. All three drugs induced apoptosis in these cell lines, as
indicated by the presence of PARP cleavage products in cell
Figure 3. Erlotinib-Induced Cell Death Is Mediated by the Intrinsic Pathway of Apoptosis
(A) Erlotinib induces time- and dose-dependent cytochrome c release in H3255 cells. H3255 cells were treated with different concentrations of drug for
24 h, or 100 nM erlotinib for the indicated times. Cytosolic fractions were obtained through differential centrifugation as described in the Methods and
used for immunoblotting.
(B) Erlotinib induces colocalization of BAX and cytochrome c in PC-9 cells undergoing apoptosis. Cells were grown in Lab-Tek II chambers and treated
with 100 nM erlotinib or DMSO for 48 h, fixed and immunostained with antibodies against BAX (green) and cytochrome c (red) or with DAPI to detect
DNA (blue). Cells were imaged by confocal microscopy.
(C) PC-9 cells were stably transfected with cDNAs encoding BCL-xL. Two stable clones (B1 and B2) showed elevated levels of BCL-xL compared to cells
transfected with expression vector alone, as shown by immunoblotting.
(D) BCL-xL overexpression blocks erlotinib-induced apoptosis in PC-9 cells. Stable clones expressing empty vector (V) or BCL-xL (B1 and B2) were treated
with DMSO or 100 nM erlotinib for 48 h and percentages of apoptotic cells were estimated using annexin V/PI apoptosis assays.
(E) BCL-xL overexpression does not affect the ability of erlotinib to inhibit EGFR signaling pathways in PC-9 cells. Stable clones were treated with 100 nM
erlotinib for 6 h. The phosphorylation status of proteins involved in EGFR signaling was examined by immunoblotting. t, total protein; p, phospho-
protein.
doi:10.1371/journal.pmed.0040294.g003
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BIM and Erlotinib-Induced Apoptosislysates (Figure 4D). Consistent with these ﬁndings, all three
EGFR inhibitors induced the expression and dephosphor-
ylation of BIM EL. These data indicate that the induction of
BIM is triggered by various EGFR inhibitors and is not a
speciﬁc effect of erlotinib.
BIM Is Required for Erlotinib-Induced Apoptosis
To examine the role of BIM in erlotinib-induced cell killing
in more detail, we used siRNAs to suppress BIM expression
almost completely in both H3255 and PC-9 cells (Figure 5A).
Two independent siRNAs were utilized to knock down BIM in
PC-9 cells.
Knockdown effectively abolished erlotinib-induced killing
in both cell lines (Figure 5B). By comparison, cells transfected
with control siRNA against GFP continued to undergo
apoptosis in response to erlotinib. In each of three
independent experiments, the difference in percent of
apoptotic cells induced by erlotinib in H3255 and PC-9 cells
was statistically signiﬁcant (p ¼ 0.001 for H3255 with BIM
Figure 4. BIM Status Is Dramatically Altered by Inhibition of EGFR Kinase Activity in Cells Dependent upon Mutant EGFR Signaling for Survival
(A) Effects of erlotinib treatment on proapoptotic and antiapoptotic proteins in H3255 cells. H3255 cells were treated with different concentrations of
erlotinib for 24 h. Cell lysates were examined by immunoblotting using antibodies specific for the indicated proteins.
(B) Erlotinib induces dephosphorylation and increased levels of BIM in drug-sensitive PC-9 cells but not in drug-resistant H1650 or H1975 cells. Cells
were treated with different concentrations of erlotinib for 24 h. Cell lysates were analyzed by immunoblotting with antibodies that recognize the
indicated proteins.
(C) Increased gene transcription contributes to the induction of BIM protein expression after erlotinib treatment. H3255 cells were treated with erlotinib
(100 nM) in the presence or absence of actinomycin D (5 lg/ml) for the indicated times. Cell lysates were analyzed by immunoblotting using the
indicated antibodies.
(D) Multiple EGFR kinase inhibitors affect BIM status. H3255 (left blot) and PC-9 (right blot) cells were treated with erlotinib (100 nM), gefitinib (1 lM), or
CL-387,785 (100 nM) for 24 h and 48 h, respectively. Cell lysates were analyzed by immunoblotting with antibodies that recognize the indicated
proteins.
doi:10.1371/journal.pmed.0040294.g004
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siRNA-1 and  2, respectively; Welch two-sample t-test). As
another comparison, we also examined the effect of knock-
down of a different proapoptotic protein, BAD, on erlotinib-
induced apoptosis in H3255 cells. Here, no statistically
signiﬁcant difference in rates of apoptosis was observed (p ¼
0.13; Welch two-sample t-test) (Figure 5B). However, despite
multiple attempts with different siRNAs, we were unable to
abolish BAD expression completely (unpublished data). Thus,
we could not entirely exclude the possibility that BAD is also
required for erlotinib-induced cell death.
EGFR Signaling Influences BIM Expression and
Phosphorylation Status Mainly via the ERK Pathway
Mutant EGFRs activate both the ERK and phosphatidyli-
nositol 3-kinase/protein kinase B (PI3K/AKT) signaling path-
ways [4,6]. Both cascades have been shown to regulate BIM
phosphorylation, degradation, and activity, although in
different cellular and biological contexts [33,34,37]. Since
EGFR kinase inhibition by erlotinib diminishes activation of
both ERK and AKT pathways in drug-sensitive cells but not in
drug-resistant cells (Figures 1 and 6A), we next asked whether
inhibition of both pathways is required for the increased
expression and dephosphorylation of BIM. Thus, we exam-
ined the status of phospho-ERK, -AKT, and BIM in lysates
from H3255 cells treated with erlotinib and compared results
to those obtained from cells exposed to a mitogen-activated
protein kinase kinase (MAP2K or MEK) inhibitor (PD98059 or
U0126, which affect the ERK pathway), a PI3K inhibitor
(wortmannin or LY294002), or both. We focused our
attention primarily on the BIM EL isoform, because it is the
major isoform detected in these cells, and the BIM EL
isoform, but not BIM L and S, contains phosphorylation sites
for ERK and AKT [33,34].
Treatment of H3255 cells with either MEK inhibitor led to
an increase in BIM expressi o nl e v e l sa sw e l la st h e
dephosphorylation of BIM (as indicated by the faster
migrating form) (Figure 6A)—changes similar to that seen
in erlotinib-treated cells. Treatment with the PI3K inhibitors
alone had minimal effects on either BIM expression levels or
phosphorylation status. Lysates from cells treated with the
combination of MEK (U0126, Figure 6A) and PI3K inhibitors
(wortmannin or LY294002, Figure 6A) did not show any
additive effects on the induction of BIM EL, when compared
with cells treated with the MEK inhibitor treatment alone.
These data suggest that mutant EGFRs inﬂuence BIM
expression and phosphorylation status mainly through the
ERK signaling pathway. More precise mechanisms of BIM
regulation remain to be elucidated.
Finally, to begin to determine how EGFR signaling affects
BIM in an isolated cell system, we examined the effect of EGF
stimulation on Bim in NIH 3T3 cells stably transfected with
cDNAs encoding wild-type EGFR [25]. These mouse ﬁbro-
blasts express very low levels of endogenous Egfr and its
heterodimeric Erbb family members (i.e., Erbb2, Erbb3, and
Erbb4). As expected, addition of exogenous EGF to serum-
starved cells induced a rapid and massive phosphorylation of
the receptor within 15 min, followed by a time-dependent
decay in receptor activity (Figure 6B). Levels of total EGFR
decreased after EGF stimulation, presumably due to internal-
ization and lysosomal degradation of the receptor. These
changes were accompanied by transient increases in both Erk
and Akt signaling. In parallel with these changes, EGF
stimulation induced a rapid phosphorylation of Bim as well
as a decrease in Bim protein levels; others have shown that
these changes correlate with decreased Bim activity [34,38].
BIM levels were restored quickly as levels of phospho-EGFR
diminished. Thus, Bim protein levels and phosphorylation are
tightly regulated by the EGFR signaling pathway. Moreover,
Figure 5. The BH3-Only Protein BIM Is Required for Erlotinib-Induced
Apoptosis
(A) Knockdown of BIM expression by siRNA transfection. H3255 and PC-9
cells were transiently transfected with various siRNAs against GFP, BIM,o r
BAD. Two different siRNAs against BIM were used in PC-9 cells. Cells were
harvested 48 h after transfection and lysates were examined for BIM
expression by immunoblotting.
(B) Knockdown of BIM expression completely blocks erlotinib-induced
apoptosis. At 48 h post siRNA transfection, H3255 cells were treated with
DMSO or 100 nM erlotinib for an additional 24 h. At 24 h after siRNA
transfection, PC-9 cells were treated with DMSO or 100 nM erlotinib for
an additional 48 h. Cells were harvested, and the percentage of
apoptotic cells was determined by annexin V/PI apoptosis assays.
Annexin V-positive cells were calculated as apoptotic cells. The average
percent 6 standard deviation of apoptotic cells induced by erlotinib in
cells transfected with GFP, BIM,o rBAD siRNA was derived from three
independent experiments. The indicated p-values were calculated using
a Welch two-sample t-test.
doi:10.1371/journal.pmed.0040294.g005
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BIM and Erlotinib-Induced ApoptosisEGFR stimulation by ligand can lead to changes suggestive of
decreased BIM activity.
Bim Expression and Phospho-EGF Receptor Status Are
Inversely Correlated in Mouse Models
We had hoped to extend our studies on the role of BIM in
kinase inhibitor-induced apoptosis to human mutant EGFR
tumor specimens. However, such studies would require
precisely timed re-biopsies of tumors in patients just
initiating treatment. Since such samples are not currently
available, we took advantage of established mutant EGFR
mouse lung tumor models. Speciﬁcally, we examined the
relationship between levels of phospho-EGFR and Bim in
tumors induced in transgenic mice that conditionally express
mutant L858R EGFRs in lung epithelial cells under the
control of tetracycline regulation [9]. We previously showed
that treatment with erlotinib eliminated disease within lung
tumor-bearing animals [9]. Here, tumor-bearing transgenic
animals (as determined by magnetic resonance imaging) were
treated with a single dose of vehicle (n ¼ 5) or erlotinib (50
mg/kg; n¼5) intraperitoneally and humanely killed 13 h later.
Lungs from all EGFR-transgenic animals expressed the
induced oncoprotein, as measured by immunoreactivity of
lysates with antisera against the speciﬁc L858R EGFR [9]
(Figure 7A). At 13 h after treatment, lung tissues from
control-treated animals expressed high levels of phosphory-
lated EGFR, while EGFR phosphorylation was abolished in
lungs from erlotinib-treated mice.
We next determined corresponding Bim levels in the
mouse lung lysates, using the same BIM antisera as used above
to interrogate the human cell lines. Lungs from vehicle-
treated L858R mice displayed low levels of Bim EL (Figure
7A). By contrast, corresponding tissue from erlotinib-treated
animals displayed elevated levels of Bim. We detected only
very low levels of Bim L and did not detect dephosphorylated
Bim for unknown reasons (unpublished data). Similar results
were obtained by parallel analyses of lung tumor nodules
derived from mice expressing the EGFR L747–S752 deletion
mutant (n ¼ 4) (Figure 7B). By contrast, Bim levels remained
constant in non-transgenic mice lacking tumors and treated
with either vehicle (n ¼ 2) or erlotinib (n ¼ 3) in the same
manner (Figure 7C).
To verify these results even further using homogenous
tissue samples, we treated athymic nude mice bearing PC-9
xenografts with placebo (n ¼ 4) or erlotinib (25 mg/kg 3 2
doses; n ¼ 4) and examined the status of EGFR phosphor-
ylation and BIM in xenograft lysates. As expected, immuno-
blotting analyses demonstrated that while EGFR was
dephosphorylated after erlotinib administration, BIM EL
expression was induced (Figure 7D). Conversely, xenograft
lysates from placebo-treated animals showed the opposite
result—high levels of phospho-EGFR and low levels of BIM
EL. Collectively, these studies with both transgenic and
xenograft mouse models support our earlier conclusions
from in vitro studies on human cells that erlotinib augments
the concentration of Bim in lung adenocarcinomas depend-
ent upon mutant EGFR for survival.
ABT-737 Significantly Enhances Erlotinib-Induced
Apoptosis in Drug-Sensitive Lung Adenocarcinoma Cells
ABT-737 is a small-molecule BCL2 antagonist that has
antitumor activity, most notably as a single agent against
small cell lung cancers, lymphomas, and leukemias [39,40].
ABT-737 also displays synergistic cytotoxicity with chemo-
therapeutic agents (e.g., paclitaxel) against ‘‘less sensitive’’
cancer cell lines, including ones of non-small cell lung cancer
origin (without EGFR mutations) [40]. The drug as a single
agent has relatively little effect on imatinib-sensitive K562
cells, which harbor the BCR-ABL translocation; however, its
addition to imatinib greatly enhances imatinib-induced cell
death in vitro [23]. Taken together with our ﬁndings that
mutant EGFR-dependent cells die via the intrinsic pathway of
Figure 6. The Status of BIM Is Influenced by EGFR Signaling
(A) BIM phosphorylation and protein levels are influenced by the ERK signaling pathway. H3255 cells were treated with a MEK inhibitor (PD98059, 50
lM; U0126, 10 lM), a PI3K inhibitor (LY294002, 50 lM; wortmannin, 100 nM every 2 h), both, or 100 nM erlotinib for 8 h. Cell lysates were analyzed by
immunoblotting using the indicated antibodies.
(B) NIH 3T3 cells transfected with wild-type EGFR cDNAs were serum-starved overnight and then stimulated with 100 ng/ml human EGF. After the
indicated times, cells were harvested. Lysates were analyzed by immunoblotting, using the indicated antibodies. t, total protein; p, phospho-protein.
doi:10.1371/journal.pmed.0040294.g006
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BIM and Erlotinib-Induced Apoptosisapoptosis, we hypothesized that the intrinsic pathway could
be manipulated by ABT-737 to enhance erlotinib-induced
cell killing of EGFR mutant lung cancer cells.
To verify this hypothesis, we treated H3255 cells for 6 h
with different concentrations of ABT-737 alone or in
combination with 50 nM erlotinib. Cells were then analyzed
for the induction of apoptosis by annexin V/PI assays.
Whereas erlotinib or ABT-737 alone induced minimal
increases in the percent of apoptotic cells, the combination
of the EGFR inhibitor and the BCL2 antagonist signiﬁcantly
increased the percentage of apoptotic cells, in a manner
dependent upon the concentration of ABT-737 (Figure 8A).
Similar results were obtained with PC-9 cells treated for 24 h
(Figure 8B). Cotreatment with erlotinib and the inactive ABT-
737 enantiomer, which served as a negative control, had no
such effect in either set of cells. These data indicate that
BCL2 antagonists such as ABT-737 can be combined with
erlotinib to enhance cell death in mutant EGFR-dependent
cells.
Discussion
Selective EGFR kinase inhibitors such as geﬁtinib and
erlotinib induce tumor shrinkage in the majority of patients
harboring mutant EGFR lung adenocarcinomas [41]. Studies
with cell lines and mouse lung tumor models suggest that such
responses involve cell death, but the underlying mechanisms
have not been well elucidated. Here, we sought to character-
ize pathways of apoptosis induced by this class of agents in
mutant EGFR-dependent lung adenocarcinoma cells. An
Figure 7. In Vivo Correlation of BIM/Bim Expression and Mutant EGFR Activity
(A and B) Lung tumor-bearing mice that express a tetracycline-inducible L858R mutant (EGFR
L858R) (A) or an exon 19 deletion mutant (EGFR
DL747–S752) (B)
were treated with a single dose of either vehicle control or 50 mg/kg erlotinib intraperitoneally. After 13 h, animals were sacrificed and lungs were
harvested. Whole lung lysates (for EGFR
L858R) or tumor nodule lysates (for EGFR
DL747–S752) were probed by immunoblotting using the indicated
antibodies. C
þ/L
þ, CCSP-rtTA/tet-o-EGFR
L858R bitransgenic mouse; C
þ/Del
þ, CCSP-rtTA/tet-o-EGFR
DL747-S752 bitransgenic mouse; pEGFR Y1092, EGFR
phosphorylated at a tyrosine residue at position 1092).
(C) Lungs from nontransgenic mice and lacking tumors were treated with placebo or erlotinib in the same manner and analyzed for BIM and EGFR
expression status. C
 /L
 , nontransgenic mouse.
(D) Nude mice bearing PC-9 xenografts were treated with either vehicle control or 25 mg/kg erlotinib intraperitoneally every 12 h 3 2 doses. The
xenografts were dissected 24 h after the first injection, and tumor lysates were probed by immunoblotting using the indicated antibodies.
doi:10.1371/journal.pmed.0040294.g007
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identiﬁcation of even more effective therapeutic strategies.
The studies were motivated by the fact that despite inducing
dramatic clinical and radiographic tumor responses, geﬁtinib
and erlotinib rarely induce complete responses and do not
cure patients.
Using a panel of human lung cancer cell lines that harbor
EGFR mutations, we show that mutant EGFR-dependent cells
with nanomolar sensitivity to erlotinib undergo G1 cell cycle
arrest and cell death in response to kinase inhibition. Cell
death is mediated through the intrinsic apoptotic pathway:
cells release cytochrome c from mitochondria, they display
altered localization of the proapoptotic protein BAX, and
apoptosis can be blocked by overexpression of the anti-
apoptotic protein BCL-xL.
We also found that in cells dependent upon mutant EGFR
signaling for survival, EGFR kinase inhibition leads to
induced levels and dephosphorylation of BIM, a member of
the proapoptotic BH3-only family of BCL2-related proteins.
Importantly, these changes, which have been shown to
enhance the proapoptotic activity of BIM [33,34], are
required for erlotinib-induced cell death; knockdown of
BIM expression by RNA interference completely eliminates
drug-induced cell killing in vitro, and erlotinib dramatically
induces BIM levels in cell lines that die but not in cell lines
resistant to the drug. Consistent with these in vitro ﬁndings,
lungs from transgenic mice bearing mutant EGFR-driven
lung adenocarcinomas and xenografts of PC-9 cells display
increased concentrations of Bim shortly after erlotinib
treatment.
BIM has been previously implicated in signaling cell death
following cytokine withdrawal [42]. This BH3-only protein
has also been shown to be necessary for imatinib-induced
killing of BCR-ABL-dependent leukemic cells in vitro (human
cells) and in vivo (mice) [23]. The latter study found that only
knockdown of Bim and Bad together by RNA interference
could completely eliminate imatinib-induced killing. Here we
found that knockdown of BIM alone by siRNAs was sufﬁcient
to prevent erlotinib-induced cell death in human lung cancer
cells. Discrepancies between killing mechanisms in leukemic
cells sensitive to imatinib and lung adenocarcinoma cells
sensitive to EGFR inhibitors could be explained by different
cell types of origin and/or different experimental procedures.
Nevertheless, taken together, these ﬁndings suggest that the
Figure 8. ABT-737 Significantly Enhances Erlotinib-Induced Apoptosis in Drug-Sensitive Lung Adenocarcinoma Cells
(A) H3255 cells were cotreated with 50 nM erlotinib and different concentrations of ABT-737 for 6 h. The percentage of apoptotic cells for each drug
combination was determined by annexin V/PI apoptosis assays.
(B) PC-9 cells were cotreated with 50 nM erlotinib and different concentrations of ABT-737 for 24 h. The percentage of apoptotic cells for each drug
combination was determined by annexin V/PI apoptosis assays. The enantiomer of ABT-737 was used a negative control. ABT, ABT-737; Enant,
enantiomer.
doi:10.1371/journal.pmed.0040294.g008
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BIM and Erlotinib-Induced Apoptosisinduction of BIM is a common apoptotic mechanism shared
by both hematopoietic and epithelial tumor cells that depend
upon kinase signaling for survival.
The status of BIM appears to be regulated at multiple
points. Transcriptional proﬁling of erlotinib-treated cells and
immunoblotting analysis of cells co-treated with erlotinib and
an RNA polymerase II inhibitor indicate that the induction of
BIM occurs at least in part at the transcriptional level.
Moreover, studies of Bim in NIH 3T3 (mouse) cells trans-
fected with EGFR cDNAs and in human lung adenocarcinoma
cell lines that harbor EGFR mutations indicate that Bim
phosphorylation status is inﬂuenced by perturbation of EGFR
signaling. Use of speciﬁc PI3K/AKT and ERK pathway
inhibitors on drug-sensitive EGFR mutant cells suggests that
the ERK pathway predominantly inﬂuences BIM status
downstream of EGFR. However, others have shown that
H3255 and PC-9 cells treated with a more potent and
selective MEK1/2 inhibitor, PD0325901 (Pﬁzer), do not
undergo apoptosis (Dr. David Solit, Memorial Sloan-Ketter-
ing Cancer Center, New York, personal communication). This
ﬁnding suggests that (1) while BIM induction is required for
erlotinib-induced apoptosis, it may not be sufﬁcient to
provoke cell death, and (2) other signaling components
downstream of EGFR are also likely to be involved in
inducing apoptosis of these cells.
At the clinical level, our results have several implications.
Since drug-sensitive EGFR mutant cells die via the intrinsic
pathway of caspase activation, molecules within this cascade
could inﬂuence both sensitivity and/or resistance of EGFR
mutant lung tumor cells to EGFR kinase inhibitors. Con-
versely, manipulation of this pathway could be a therapeutic
strategy to enhance the death of cells that depend upon
mutant EGFR signaling for survival. Indeed, the fact that the
BCL2 antagonist ABT-737 signiﬁcantly enhances erlotinib-
induced cell killing provides proof-of-principle that such an
approach may achieve greater and more durable responses to
EGFR inhibitors in patients whose lung tumors harbor EGFR
kinase domain mutations.
Supporting Information
Figure S1. Erlotinib Induces Caspase 3/7 Activation in Drug-Sensitive
Lung Adenocarcinoma Cell Lines That Harbor EGFR Mutations
Cell lines were treated with either DMSO or different concentrations
of erlotinib in 96-well plates for the indicated times. Caspase 3/7
activity per well was measured as described in the Methods. Values
represent the mean 6 standard deviation of three independent
experiments.
Found at doi:10.1371/journal.pmed.0040294.sg001 (8.2 MB TIF).
Figure S2. MCL1 Elimination Is Not Required for Erlotinib-Induced
Apoptosis in H3255 Cells
Cells were treated with erlotinib (100 nM) alone or with erlotinib (100
nM) and the proteasome inhibitor MG132 (10 lM) for the indicated
times. Cell lysates were analyzed by immunoblotting with the
indicated antibodies.
Found at doi:10.1371/journal.pmed.0040294.sg002 (8.2 MB TIF).
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/) accession numbers for
the human genes and proteins discussed in this article are BAD
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(also known as BCL2L11; NM_138621), EGFR (NM_005228), MCL1
(NM_021960).
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Editors’ Summary
Background. Lung cancer, a common type of cancer, has a very low cure
rate. Like all cancers, it occurs when cells begin to divide uncontrollably
because of changes (mutations) in their genes. Chemotherapy drugs kill
these rapidly dividing cells but, because some normal tissues are
sensitive to these agents, it is hard to destroy the cancer without causing
serious side effects. Recently, ‘‘targeted’’ therapies have brought new
hope to some patients with cancer. These therapies attack the changes
in cancer cells that allow them to divide uncontrollably but leave normal
cells unscathed. One of the first molecules for which a targeted therapy
was developed was the epidermal growth factor receptor (EGFR). In
normal cells, messenger proteins bind to EGFR and activate its ‘‘tyrosine
kinase,’’ an enzyme that sticks phosphate groups on tyrosine (an amino
acid) in other proteins. These proteins then tell the cell to divide.
Alterations to this signaling system drive uncontrolled cell division in
some cancers so blocking the EGFR signaling pathway should stop these
cancers growing. Indeed, some lung cancers with mutations in the
tyrosine kinase of EGFR shrink dramatically when treated with gefitinib or
erlotinib, two tyrosine kinase inhibitors (TKIs).
Why Was This Study Done? TKI-sensitive lung cancers shrink when
treated with TKIs because of drug-induced cell death, but what are the
molecular mechanisms underlying this death? A better understanding of
how TKIs kill cancer cells might provide new insights into why not all
cancer cells with mutations in EGFR (the gene from which EGFR is made)
are sensitive to TKIs. It might also uncover new targets for therapy. TKIs
do not completely kill lung cancers, but if the mechanism of TKI-induced
cell death were understood, it might be possible to enhance their effects.
In this study, the researchers have investigated how cell death occurs
after kinase inhibition in a panel of human lung cancer cell lines (cells
isolated from human tumors that grow indefinitely in dishes) that carry
EGFR mutations.
What Did the Researchers Do and Find? The researchers show, first,
that erlotinib induces a type of cell death called apoptosis in erlotinib-
sensitive cell lines but not in resistant cell lines. Apoptosis can be
activated by two major pathways. In this instance, the researchers report,
the so-called ‘‘intrinsic’’ pathway activates apoptosis. This pathway is
stimulated by proapoptotic members of the BCL2 family of proteins and
is blocked by antiapoptotic members, so the researchers examined the
effect of erlotinib treatment on the expression of BCL2 family members
in the EGFR mutant cell lines. Erlotinib treatment increased the
expression of the proapoptotic protein BIM in sensitive but not in
resistant cell lines. It also removed phosphate groups from BIM—
dephosphorylated BIM is a more potent proapoptotic protein. Con-
versely, blocking BIM expression using a technique called RNA
interference virtually eliminated the ability of erlotinib to kill EGFR
mutant cell lines. The researchers also report that erlotinib treatment
increased BIM expression in erlotinib-sensitive lung tumors growing in
mice and that an inhibitor of the anti-apoptotic protein BCL2 enhanced
erlotinib-induced death in drug-sensitive cells growing in dishes.
What Do These Findings Mean? These findings indicate that BIM
activity is essential for the apoptosis triggered by TKIs in drug-sensitive
lung cancer cells that carry EGFR mutations, and that treatment of these
cells with TKIs induces both the expression and dephosphorylation of
BIM. The finding that the intrinsic pathway of apoptosis activation is
involved in TKI-induced cell death suggests that changes in this pathway
(possibly mutations in some of its components) might influence the
sensitivity of EGFR mutant lung cancers to TKIs. Finally, these findings
suggest that giving drugs that affect the intrinsic pathway of apoptosis
activation at the same time as TKIs might further improve the clinical
outcome for patients with EGFR mutant tumors. Such combinations will
have to be tested in clinical trials before being used routinely.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040294.
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